Has Market Sentiment Shifted on Bath & Body Works?

This afternoon we watched Bath & Body Works rise 6.8% to a price of $31.75 per share. The mid-cap Specialty Retail company is now trading -29.62% below its average target price of $45.11. Analysts have set target prices ranging from $27.0 to $68.0 per share for Bath & Body Works, and have given the stock an average rating of buy.

Bath & Body Works's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 5.0%. The stock's short ratio is 3.19. Only 0.46% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.

Another number to watch is the company's rate of institutional share ownership, which now stands at 93.8%. In conclusion, we believe there is mixed market sentiment regarding Bath & Body Works.

Institutions Invested in Bath & Body Works

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 11% 25,621,623 $813,486,530
2023-06-30 Lone Pine Capital Llc 7% 16,356,915 $519,332,051
2023-09-30 Blackrock Inc. 7% 16,258,320 $516,201,660
2023-06-30 Third Point, LLC 6% 13,850,000 $439,737,500
2023-06-30 T. Rowe Price Investment Management, Inc. 5% 11,745,372 $372,915,561
2023-06-30 State Street Corporation 4% 9,782,690 $310,600,407
2023-06-30 Price (T.Rowe) Associates Inc 4% 8,383,184 $266,166,092
2023-06-30 Atreides Management, LP 2% 5,641,028 $179,102,639
2023-06-30 JP Morgan Chase & Company 2% 5,619,748 $178,426,999
2023-09-30 Primecap Management Company 2% 5,618,075 $178,373,881
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.